ASH 2023 | Update of a Phase I trial investigating lintuzumab-Ac225 plus venetoclax in R/R AML

MCL1 is a known mediator of venetoclax resistance, and the promotion of its degradation through DNA damage has been shown to increase the sensitivity of a cell to venetoclax in vitro. Lintuzumab-Ac225, a monoclonal antibody radio-conjugate, emits alpha-radiation, which selectively targets the CD33 cell surface antigen on acute myeloid leukemia (AML) cells and results in DNA breaks that promote MCL1 degradation. Gary Schiller, MD, University of California, Los Angeles, CA, presents the updated results from a Phase I study investigating targeted radiotherapy with lintuzumab-Ac225 in combination with venetoclax in relapsed/refractory (R/R) AML. The combination exhibited a manageable safety profile, and at the highest dose level, two-thirds of patients responded to treatment. Dr Schiller highlights that prolonged hospitalization of patients following administration of the drug was not required. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.